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Craniopharyngiomas are partly cystic embryogenic malformations of the sellar and parasel-
lar region, with up to half the 0.5–2.0 new cases per million population per year occur in
children and adolescents. Diagnosis proﬁle for pediatric and adult craniopharyngioma is
characterized by a combination of headache, visual impairment, and polyuria/polydipsia,
which can also include signiﬁcant weight gain. In children, growth retardation, and/or pre-
mature puberty often occur later or postoperatively. Recommended therapy with favorable
tumor localization is complete resection; with unfavorable tumor localization (optic nerve
and/or hypothalamic involvement), consensus is still pending whether a limited resection
followed by local irradiation is more prudent. Even though overall survival rates are high
(92%), recurrences after complete resection and progressions after incomplete resection
can be expected. Accordingly, a randomized multinational trial (KRANIOPHARYNGEOM
2007) has been established to identify optimal diagnosis, treatment (particularly the ideal
time point of irradiation after incomplete resection), and quality of life strategies of this
chronic disease – most notably the morbid hypothalamic obesity in ∼50% of long-term
survivors. We report on craniopharyngioma origins, its pathological manifestations, and
speciﬁc challenges these sequelae pose regarding diagnosis, treatment, and life-long
multi-discipline quality of life management for both adult and childhood craniopharyngioma
patients.
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INTRODUCTION
Craniopharyngioma is a rare, non-glial, non-malignant intracra-
nial tumor derived from a malformation of embryonal tissue. The
pathogenesis of craniopharyngioma is currently debated between
twoprimary hypotheses: one describes tumor origin as ectodermal
remnants of Rathke’s pouch; the second argues craniopharyn-
gioma represents a malformation of residual embryonal epithe-
lium of the anterior pituitary gland and anterior infundibulum
(Garré and Cama, 2007; Müller, 2010). Anywhere from 30 to 50%
of the 0.5 to 2 cases per million persons per year manifest dur-
ing childhood and adolescence (Bunin et al., 1998; Nielsen et al.,
2011), representing 1.2–4% of all childhood intracranial tumors.
In childhood and adolescence, histological type is usually adaman-
tinomatous with cyst formation (Müller-Scholden et al., 2001;
Rushing et al., 2007). Incidences of adult onset craniopharyn-
gioma (usually between ages 50 and 75) most often present with a
squamous-papillary histological type (Rushing et al., 2007). More
than 70% of craniopharyngioma of the adamantinomatous type
bear a mutation of the β-catenin gene, which is not detectable in
the papillary type of craniopharyngioma (Hölsken et al., 2010).
The German Childhood Cancer Registry obtained data on 496
patients in whom a craniopharyngioma was diagnosed at age
≤18 years from 1980 to 2007. Of these, 451 patients (91%) were
younger than 15 years-of-age at the time of diagnosis. The sex ratio
was 1:1 and the median age at primary diagnosis was 8.6 years;
survival rate (1980–2007) was 97% at 3 years, 96% at 5 years, and
93% at 10 years after diagnosis. Patients who were diagnosed and
treated in the 1980s had a lower survival rate than those diagnosed
in the 1990s. For example, the survival rate at 5 years was 91% for
patients diagnosed in the 1980s versus 98% for those diagnosed in
the 1990s (Müller et al., 2003c). This observation is supported by
other reports (Sherlock et al., 2010), indicating that mortality is
increased in childhood craniopharyngioma patients compared to
general population.
DIAGNOSIS – CLINICAL MANIFESTATIONS AND IMAGING
METHODS
A background study of craniopharyngioma patients reveals ini-
tial symptoms often occur long before diagnosis is made (Müller,
2010, 2011), the non-speciﬁc manifestations of increased intracra-
nial pressure such as headache and nausea often going unrec-
ognized as primary symptoms of craniopharyngioma. Other
manifestations of the craniopharyngioma diagnostic proﬁle can
include visual impairment (62–84%) and endocrine deﬁcits (52–
87%; Figure 1). Craniopharyngioma tumors that involve the
hypothalamic–pituitary axis can affect the secretion of growth
hormone (75%), gonadotropins (40%), adrenocorticotropic hor-
mone (ACTH; 25%), and thyroid-stimulating hormone (TSH;
25%). Growth impediment caused by these hormonal distur-
bances often appears as early as 12months of age; however, prema-
ture puberty and/or unmanageable weight gain are more often the
precipitating factors preceding clinical diagnosis in older children
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FIGURE 1 | Manifestations before diagnosis of craniopharyngioma in
children and adolescents. Frequency of occurrence of each manifestation
before diagnosis (blue) and frequency of occurrence as the initial
manifestation (red). The median time (month) from the appearance of each
initial manifestation until diagnosis is indicated above each red column. In the
overall group, the median time from the initial manifestation of disease until
diagnosis was 12months, with a range of 0.01–96months. (Modiﬁed from
Müller et al., 2003c, with the kind permission of Springer).
(Müller, 2010). In summary, young children presenting symptoms
of decreased growth rate, older children presenting symptoms of
premature puberty and/or unmanageable weight gain, patients
(adults or children) presenting headache, visual impairment,
and/or unmanageable weight gain, and/or polydipsia/polyuria
should arouse suspicion of craniopharyngioma (Müller, 2010).
The combination of solid, cystic, and calciﬁed tumor com-
ponents is an important radiological clue to craniopharyngioma
diagnosis (Warmuth-Metz et al., 2004). The signal intensity of
craniopharyngioma in magnetic resonance imaging (MRI) is
highly variable, as it depends on the protein content of the cysts.
Solid tumor portions and cyst membranes appear isointense in
T1-weighted images, often with a mildly heterogeneous struc-
ture (Figure 2). MRI before and after gadolinium application is
the standard imaging for detection of craniopharyngioma, but
because CT is the only way to detect or exclude calciﬁcation,which
is found in approximately 90% of tumors, (Warmuth-Metz et al.,
2004),a sellar or parasellarmass detectedonMRI shouldbe further
imaged by native CT for detection of calciﬁcations.
TREATMENT – CHALLENGES AND STRATEGIES
Disturbance of cerebrospinal ﬂuid (CSF) ﬂow often causes hydro-
cephalus, which, depending on severity, must be stabilized by
surgical treatment. Tumor resection is the ﬁrst-choice treatment
for restoring normal CSF ﬂow, but a pre-surgery shunt operation
may also be required. For a craniopharyngioma with large cystic
components, stereotactic, or open implantation of an intracys-
tic catheter is a proven treatment both for the relief of pressure
and, in some cases, for the instillation of sclerosing substances
(bleomycin). An intracystic catheter with a subcutaneous reser-
voir can be effective for reducing cyst volume and is particularly
appropriate for infants and toddlers where extending the interval
until radiotherapy or surgical resection is advantageous in some
cases. For patients experiencing preoperative visual impairment
due to large cysts exerting pressure on the optic nerve, a two-staged
treatment approach is proposed,with cyst drainage to relieve pres-
sure and improve vision, followedby resection (Choux et al., 1991).
After preoperative assessment of calciﬁcations by CT, the rec-
ommended therapy for favorably tumor localized tumors is com-
plete resection while preserving visual, hypothalamic, and pitu-
itary functions (Choux et al., 1991;Müller, 2006).However, radical
resection, especially in infants and small children, is problematic
due the heightened risk of surgically induced deﬁcits (mainly
hypothalamic) and the susceptibility of children to recurrence
(23%), even in apparently complete resections. For topographical–
anatomical reasons, transsphenoidal surgery is the proven neuro-
surgical technique for minimizing disturbance to these structures
(Fahlbusch et al., 1999). Following postoperative MRI conﬁrma-
tion of complete resection, a post-surgical native CT of the sel-
lar/parasellar area is recommended for reconﬁrmationof complete
resection. A right frontotemporal operative approach is standard,
although localization of craniopharyngioma should dictate the
approach. Intrasellar craniopharyngioma can be approached via
transsphenoidal route. However, childhood craniopharyngioma
usually extends to the suprasellar area and must be removed
through a transcranial approach. For topographical–anatomical
reasons, transsphenoidal surgery has proven advantageous for
minimizing disturbance to hypothalamic functions (Fahlbusch
et al., 1999).
For unfavorably localized tumors (optic nerve and/or hypo-
thalamic involvement), a limited resection followed by local irra-
diation is statistically favorable: the risk of progression is 71–90%
without postoperative radiotherapy (Figure 3), but drops to 21%
if combined with postoperative radiotherapy (Becker et al., 1999;
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FIGURE 2 | Degree of obesity in relation to the localization of
childhood craniopharyngioma. In both patients craniopharyngioma (as
indicated by arrow on MRI before surgery) could be completely resected.
Both patients had complete hypopituitarism after surgery requiring
endocrine substitution of all hypothalamic–pituitary axes. The patient
depicted in (B) developed severe obesity due to hypothalamic lesions of
suprasellar parts of craniopharyngioma (C). The patient depicted in (A)
presented with a small tumor conﬁned to the sellar region (D). After
complete resection she kept normal weight without any eating disorders.
(Modiﬁed from Müller et al., 2003c, with the kind permission of Springer).
Einhaus and Sanford, 2007). Nevertheless, neurosurgical strategies
to treat craniopharyngioma are a matter of debate in the literature
(Fischer et al., 1990; Yasargil et al., 1990; Hetelekidis et al., 1993;
Rajan et al., 1993; Merchant et al., 2002b; DiRocco et al., 2006;
Puget et al., 2006).
The difﬁculty in striking the correct decision regarding treat-
ment is reﬂected in two recent reports that reﬂect some telling
trends: the ﬁrst is Necker Hospital (Puget et al., 2007), which
historically is more surgically oriented; and the second is in
North America (Merchant et al., 2006), which historically has
practiced a more conservative approach. The North American
report states that current cases are now treated with moderate to
aggressive surgery where 42% of patients undergo limited surgery
before irradiation. Puget et al., authors of the Necker report state
that 96% of recent cases are surgically treated (23% achieving
complete resection, 73% subtotal resection), and that combined
treatment (surgical plus radiotherapy) is performed in half the
cases following subtotal resection. The trend seems to be toward
combined treatment (surgery plus post-surgical radiotherapy) in
centers with historically prevalent surgical approaches, and toward
more radical surgical treatment strategies in centers historically
conservative-oriented.
In addition to difﬁculties in deciding the degree of resection,
the timing of postoperative residual tumor irradiation remains
unclear and controversial (Regine and Kramer, 1992; Stripp et al.,
2004; Moon et al., 2005; Tomita and Bowman, 2005; Merchant
et al., 2006; Müller et al., 2006b). Some favor immediate irra-
diation following surgical procedure and some purport a wait-
and-see approach to minimize both the necessity for irradiation
and sequelae associated with radiation therapy. Proactive post-
surgical irradiation to prevent tumor progression is favored by
the above-mentioned North American Center (Merchant et al.,
2006). But even though immediate postoperative irradiation sig-
niﬁcantly delays tumor progression, progression-contingent irra-
diation is effective, reﬂected in its unaffected overall survival rates.
These contrasting approaches have been retrospectively com-
pared by three series (Stripp et al., 2004; Moon et al., 2005;
Tomita and Bowman, 2005). Moon et al., reported no overall sur-
vival rate differences between the two strategies. Tomita et al.,
reported that for those patients undergoing immediate postop-
erative irradiation after complete resection, 83% were relapse-
free after 5 years and 70% were relapse-free after 10 years. For
those undergoing incomplete resection followed by immediate
irradiation, 71% were relapse-free after 5 years and 36% were
relapse-free after 10 years. Only 9% were relapse-free after 5 years
when incomplete resection was not immediately combined with
radiation therapy. Progression-contingent irradiation achieved
similar survival- and progression-free survival rates of 90 and
70%, respectively, meaning progression-contingent irradiation
in this series also was highly effective. However, the interpre-
tation of these studies is confounding by different indications
for treatment. They also only reﬂect relapse-free survival rates
and do not include consequences of craniopharyngioma QoL
sequelae.
The target volume of irradiation is calculated based on CT
and/or MRI images. Current imaging techniques with enhanced
resolutions allow a safety margin ideally no greater than 5mm,
depending on the tumor location, size, composition (solid, cystic,
calciﬁed), and adjacent structure involvements (hypothalamic–
pituitary axis and/or optic nerve or chiasm), requiring a larger
safety margin if the hypothalamus is involved. Three-dimensional
planning and multi-ﬁeld techniques with individual ﬁeld conﬁg-
urations (collimation) are recommended to protect radiosensitive
structures and to provide a maximal dose fall-off between the
tumor and the adjacent structures (Becker et al., 1999; Einhaus
and Sanford, 2007).
Due to the low histological malignancy of craniopharyngiomas
and especially because they are located near essential structures
regulating eyesight, growth, and energy homeostasis, proton beam
therapy appears to be a promising therapeutic option, offering a
more protective radio-oncological technique than conventional
external irradiation (Baumert et al., 2004; Fitzek et al., 2006; Luu
et al., 2006). Also reported as a promising treatment technique is
the intracystic instillation of interferon alpha (Ierardi et al., 2007).
The stereotactic instillation of radioisotopes is mainly applicable
tomonocystic recurrences of craniopharyngioma,which is recom-
mended for pre-surgical treatment of large cystic tumors and for
tumors that recur after both surgery and percutaneous radiation
therapy.
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FIGURE 3 | Kaplan–Meier analyses of event-free survival rates (EFS)
depending on the extent of resection among the 117 craniopharyngioma
patients recruited in the trial KRANIOPHARYNGEOM 2000. (Modiﬁed
from Müller et al., 2010, with the kind permission of Karger).
Other therapeutic options, including stereotactic gamma-
radiotherapy (Gamma Knife), are less promising due to limited
experience; and in the case of single-dose convergence irradiation,
of little treatment value due to reasons related to radiation biology.
Beyond treatment success ratings of craniopharyngioma
related to diagnostic and treatment strategies is the experience
level of the neurosurgeon. A few studies have analyzed treatment
outcome related to the neurosurgeons’ experience (Sanford, 1994;
Boop, 2007; Müller et al., 2011b). Both Sanford and Boop report
a marked difference in outcome according to the neurosurgeons’
experiencewith the condition. Themost recent of the three reports
(Müller et al., 2011b) analyzed craniopharyngioma outcome and
prognosis relative to patient load of the treating neurosurgical
centers, ﬁnding centers with lower craniopharyngioma patient
load – and therefore relatively less experience treating cranio-
pharyngioma – tended to use more radical surgical approaches,
resulting in less favorable outcomes regarding obesity and other
QoL considerations. Current literature advises a multidisciplinary
team approach to craniopharyngioma treatment, enabling micro-
and macro-examinations of pre-surgical, intraoperative surgical,
and post-surgical radio-oncological options, as well as long-term
QoL issues.
QoL MANAGEMENT – PRE- AND POST-TREATMENT
CONSIDERATIONS
KRANIOPHARYNGEOM 2007, a prospective, European multi-
national trial (Müller et al., 2003c, 2006b; Müller and Sörensen,
2007; Müller, 2010, 2011), is currently evaluating craniopharyn-
gioma patients’ prognoses (QoL, event-free, and overall sur-
vival rates) following deﬁned therapeutic strategies. A stratiﬁed
randomization of two treatment arms is conducted with respect to
timing of postoperative irradiation (immediate irradiation versus
irradiation at the time of progression) for the subgroup of patients
≥5 years-of-age at the timeof incomplete resection (Figure 4). The
schedule of prospective data collection and the set and deﬁnition
of parameters in KRANIOPHARYNGEOM 2007 are based on a
European consensus (Müller et al., 2006a,c). The trial is open for
international recruitment (www.kraniopharyngeom.net). There
are also other current prospective studies underway on national
and multinational levels to adopt strategies tailored to risk factors
for morbidity and QoL (Garré and Cama, 2007; Puget et al., 2007).
A recent report (Müller et al., 2011b) shows that especially
tumor involvement and surgical lesions of posterior parts of hypo-
thalamic structures predisposes to adverse late effects such as
obesity and consecutively impaired quality of life (Figure 5). The
primary craniopharyngioma sequelae affecting patients’ quality
of life are visual impairment (Choux et al., 1991), hypothalamic
lesions causing neuropsychological deﬁcits (emotional instability,
rage attacks, abnormal sexual behavior, and deﬁcits of memory
and intellectual capacities; Fischer et al., 1990; Fisher et al., 1998;
Riva et al., 1998; Müller et al., 2005a,b; Pierre-Kahn et al., 2005),
and endocrine deﬁcits (including diabetes insipidus, hormonal
deﬁciencies causing growth and puberty disturbances, hyperpha-
gia and hypothalamic obesity, and eating disorders, which are
observed in 40–50% of craniopharyngioma patients (DeVile et al.,
1996b,c;Müller et al., 2001,2003b,d,2004a; Srinivasan et al., 2004).
Most patients (85–95%) suffer from multiple deﬁcits of
hypothalamic–pituitary function, ranging to complete pituitary
insufﬁciency (DeVile et al., 1996a; Merchant et al., 2002a), and full
restoration of preoperatively deﬁcient hormonal function occurs
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FIGURE 4 | Study design of KRANIOPHARYNGEOM 2007 (www.kraniopharyngeom.net; modified from Müller et al., 2006b, with the kind permission
ofThieme).
only in rare cases (Honegger et al., 1999). Growth hormone sub-
stitution therapy is reported as a well-documented effective and
safe treatment option in patients with growth hormone deﬁciency
(Lustig et al., 2003b; Müller et al., 2010). Nevertheless, the distur-
bance of hypothalamic structures by the tumor and/or its treat-
ment is considered to be the major pathogenic factor for hyper-
phagia and obesity, conﬁrmed by an imaging study assessment
of the extent of hypothalamic involvement and consequential
sequelae (DeVile et al., 1996b). Another study performed by Roth
et al. (1998) measured serum leptin levels in craniopharyngioma
patients and found signiﬁcantly elevated leptin concentrations in
relation to BMI in patients with a suprasellar tumor components,
ﬁnding that the body mass index (BMI) of affected patients posi-
tively correlated with the degree of hypothalamic damage. Normal
inhibition of appetite after eating fails to occur because of disrup-
tion of the negative feedback loop involving leptin, formed in
adipocytes, which binds to hypothalamic leptin receptors. Weight
gain occurs in craniopharyngioma patients, even when caloric
intake is similar in craniopharyngioma patients compared to
BMI-matched controls (Harz et al., 2003).
Exacerbating the management of weight gain caused by cranio-
pharyngioma and its treatment is that childrenwith craniopharyn-
gioma have a markedly lower than normal level of physical activity
caused by daytime and disturbances of circadian rhythms (Müller
et al., 2002). Initial trials with melatonin substitution in child-
hood craniopharyngioma patients have proved promising (Müller
et al., 2006c). Polysomnographic studies in craniopharyngioma
patients with severe daytime sleepiness reveal sleeping patterns
typical for secondary narcolepsy (Müller et al., 2006d), conﬁrming
this sequela to be a major contributor to depreciated QoL. Mason
et al. (2002) reported a signiﬁcant weight loss in childhood cran-
iopharyngioma patients treated with a central stimulating agent
(dextroamphetamine).
Both the cause and treatment of weight gain in craniopharyn-
gioma patients has been approached on several fronts. Lustig et al.
(2003a,b) postulated hypothalamic disinhibition of vagal output
as a cause of increased beta-cell stimulation, leading to hyper-
insulinism and obesity. In a randomized, double-blinded study,
treatment with a somatostatin analog (octreotide) to suppress
beta-cell activity resulted inweight reduction.Due to reduced con-
centrations of catecholamine metabolites in the urine of patients
with childhood craniopharyngioma correlating with the degree
of obesity and the level of physical activity, Roth et al. (2007)
hypothesized that craniopharyngioma patients’ decreased phys-
ical activity and severe obesity might be related to decreased
central sympathetic output. In another study, Roth et al. (2011)
analyzed the gastrointestinal hormones ghrelin and peptide YY
and their effect on satiety in patients with childhood cranio-
pharyngioma and obesity, supporting that reduced ghrelin secre-
tion coupled with reduced postprandial suppression of ghrelin
leads to disturbed regulation of appetite in these patients. Pep-
tide YY levels did not differ between normal weight, obese, and
very obese patients with childhood craniopharyngioma. Recently
reported (Roth et al., 2010) is a possible pathogenic role of
peripheral alpha-melanocyte-stimulating hormone in childhood
craniopharyngioma obesity. Even though initial experiences with
bariatric surgery (laparoscopic adjustable gastric banding, LAGB)
to treat severe craniopharyngioma obesity have been encouraging,
long-term follow-up will be necessary to analyze its efﬁcacy, safety,
and long-term effect on weight development (Müller et al., 2007,
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FIGURE 5 | Changes in body mass index (BMI SDS) during first
36months after diagnosis of 117 childhood craniopharyngioma
patients recruited in KRANIOPHARYNGEOM 2000 relative to the
extent of surgical hypothalamic lesions (grade 0–2).The horizontal line
in the middle of the box depicts the median. Edges of box mark the 25th
and 75th percentile. Whiskers indicate the range of values that fall within
1.5 box-lengths. (Modiﬁed from Müller et al., 2011b, with the kind
permission of BioScientiﬁca).
2011a). As of this writing, there is no generally accepted pharma-
cological nor surgical therapy for craniopharyngioma obesity.
CONCLUSION
A retrospective study of functional capacity using the FMH instru-
ment that quantiﬁes patients’ abilities to perform everyday psy-
chomotor tasks (Wolff et al., 1996) found signiﬁcantly lower rank-
ings for craniopharyngioma patients compared to age-matched
controls (Müller et al., 2003a, 2004b), with craniopharyngioma
patients’ morbid hypothalamic obesity cited as responsible for
their low functional capacity self-rating. Age-dependent differ-
ences between childhood and adult onset craniopharyngioma are
related to histological diagnosis, biological behavior, clinical man-
ifestations, treatment options and follow-up (Koranyi et al., 2001;
Attanasio et al., 2002; Kendall-Taylor et al., 2005). The Kendall-
Taylor et al. (2005) study compared childhood craniopharyngioma
with adult onset craniopharyngioma and reported a poor state
of health and QoL in both cohorts. The majority of childhood
and adult craniopharyngioma patients displayed pituitary insuf-
ﬁciency, with 60% suffering from diabetes insipidus. Nearly all
patients were overweight or obese, reporting a poor QoL. What
we can take away from this and other reports of both childhood
and adult onset craniopharyngioma is that craniopharyngioma
involves a series of chronicmorbidities ranging fromvisual impair-
ment to life-long, seemingly untreatable, unmanageable obesity
that require on-going patient monitoring to optimize their QoL.
Such monitoring provides a two-way communication platform
that serves as both a data collection medium on how sequelae
unfolds after treatment, as well as a patient-reporting medium of
new treatment options thatmay be revealed as continuing research
develops on this all-too confounding disease.
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